---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-24-000070"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:29:18.034812+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics appoints Dr. Karen Smith and Dr. Luke Walker to Board; board expands to 7 members

## Summary
- Board size increased from 5 to 7; Dr. Smith (former CMO of Jazz Pharmaceuticals) and Dr. Walker (former CMO of Harpoon Therapeutics) join.
- Dr. Smith assigned to Compensation Committee; Dr. Walker to Nominating Committee; both deemed independent under Nasdaq rules.
- Each new director received option to purchase 19,315 shares, vesting on earlier of June 13, 2025 or 2025 annual meeting.
- Dr. Smith brings over 20 years of oncology drug development (Herceptin, Vyxeos) and regulatory experience; Dr. Walker led Tukysa (tucatinib) development at Seagen.

## SEC filing metadata
- accession: 0001842952-24-000070
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/0001842952-24-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/cntx-20240904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-24-000070
- JSON: https://secwatch.observer/filing/0001842952-24-000070.json
- Plain text: https://secwatch.observer/filing/0001842952-24-000070.txt

## Key facts
- Executive change
  Dr. Karen L. Smith was appointed as Director at Context Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/0001842952-24-000070-index.htm
- Executive change
  Dr. Luke Walker was appointed as Director at Context Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On September 4, 2024, upon the recommendation of the Nominating and Corporate Governance Committee ("Nominating Committee") of the Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”), and pursuant to the Amended and Restated Bylaws of the Company, the Board increased its size from five members to seven members and appointed Dr. Karen L. Smith and Dr. Luke Walker as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000070/0001842952-24-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.